Show
Sort by
-
Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer : a study of the Belgian and Luxembourg Gynaecological Oncology Group
-
Can medical imaging identify the histopathological growth patterns of liver metastases?
-
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy
-
A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
-
- Journal Article
- A1
- open access
Pan-cancer analysis of whole genomes
-
- Journal Article
- A1
- open access
Comparative profiling of metastatic 4T1- vs. non-metastatic Py230-based mammary tumors in an intraductal model for triple-negative breast cancer
-
- Journal Article
- A1
- open access
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
-
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer
-
Pharmacokinetic effects and safety of olaparib administered with endocrine therapy : a phase I study in patients with advanced solid tumours
-
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer
-
- Journal Article
- A1
- open access
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
-
Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors : results of two phase I open-label studies
-
- Journal Article
- A2
- open access
Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals Krüppel-like factor 9 as a potential suppressor of invasive growth in breast cancer
-
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)